Back to the future: a return to psychedelic treatment models for addiction.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. The phenomenology of psilocybin: transformative insights for research and clinical practice.Frontiers in psychology · 2025
   Article
2. Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting.The International journal on drug policy · 2022
   Article
3. Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center.Frontiers in pharmacology · 2021
   Article

Corrections and comments

• Comment on
  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.2014

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as